Table 1 Summary of 8 BBLAs
Age/sex | H-H grade | Medications | Stents | Immediate results | Complications | Follow-up | Clinical outcome score |
|---|---|---|---|---|---|---|---|
50/M | I | Dual antiplatelets | Enterprise | Com | Regrowth, re-bleeding | 6 mon | 1 |
56/M | I | Dual antiplatelets | Neuroform EZ | Com | Vessel spasm | 6 mon | 0 |
37/F | IV | Tirofiban | LVIS | Com | Hydrocephalus | 8 mon | 1 |
60/F | I | Dual antiplatelets | LVIS | Com | No | 3 mon | 0 |
48/F | I | Dual antiplatelets | LVIS | Com | No | 6 mon | 0 |
46/F | III | Dual antiplatelets | LVIS | Com | No | 3 mon | 0 |
48/F | I | Dual antiplatelets | Pipeline | Com | No | 3 mon | 0 |
51/M | III | Dual antiplatelets | Pipeline | Com | Vessel spasm | 6 mon | 1 |